Neurocrine Biosciences Presents New Tardive Dyskinesia Survey Results Showing Fewer Work and School Disruptions with INGREZZA® (valbenazine) Capsules

A Neurocrine-sponsored survey found work or school disruptions among respondents with tardive dyskinesia taking INGREZZA fell from 57% before treatment to 21% afterward; average missed days per month declined from 5.6 to 2.0. In a separate post-hoc KINECT-PRO analysis, 62.2% of 45 participants with Week 24 data met the specified clinically meaningful improvement threshold for TDIS total score. The findings will be presented at the NEI Fall Congress; the employment analysis involved small populations, and the release reports no financial results or market reaction.

Analysis

NBIX — The commercial value here is incremental support for treatment persistence and broader physician confidence, not evidence of a newly enlarged addressable market. If the patient-function narrative improves adherence or reduces treatment hesitancy, it could help defend INGREZZA against Teva’s Austedo; however, these company-sponsored survey results and an open-label, post-hoc analysis do not establish comparative efficacy or a change in prescribing. The small survey and Week 24 analysis, plus retrospective reporting and attrition, limit how confidently the findings translate into real-world demand. The “work productivity” angle is also unlikely by itself to change reimbursement absent independently validated utilization or outcomes data.

Near term (days), conference visibility may support sentiment, but the findings look more like commercial reinforcement than a fundamental catalyst. Over 1–3 months, prescription trends, persistence, payer access, and management’s commercial commentary matter more than presentation reach. Over 6–18 months, sustained uptake could strengthen the franchise; class competition, tolerability, and reimbursement remain counterweights. The contrarian point: positive patient-reported outcomes may be overread as a durable sales acceleration, while the less obvious potential upside is improved persistence among treated patients—an effect these data do not quantify. Falsification: no improvement in prescription or persistence indicators, weaker commercial commentary, or evidence that payer restrictions or tolerability prevent the reported benefits from translating into continued use.

Key Decisions for Investors

• No standalone trade on this release: the evidence is supportive but not sufficiently independent or comparative to justify changing NBIX exposure.
• Treat any immediate NBIX strength as a sentiment move unless followed by better prescription, refill/persistence, or revenue indicators; do not infer a quantified sales uplift from the survey.
• Set an alert for the next NBIX update on INGREZZA demand, persistence, and payer access, and monitor competitive positioning versus Teva’s Austedo.
• Reassess a bullish thesis if commercial metrics strengthen alongside management commentary; reconsider it if uptake stalls, reimbursement tightens, or tolerability concerns impair continuation.